Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Curis, Inc.
City of Hope Medical Center
Fred Hutchinson Cancer Center
City of Hope Medical Center
Case Comprehensive Cancer Center
Cyclacel Pharmaceuticals, Inc.
Humanigen, Inc.
BioMAS Ltd
Samsung Medical Center